Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

NCT04762160 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.

NCT NCT04762160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04762160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Lead sponsor
Epizyme, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
December 15, 2020
Completion date
March 22, 2022
Enrollment
5 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma